Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.
作者信息
Ruilope Luis M, Tamargo Juan, Ruiz-Hurtado Gema
机构信息
Cardiorenal Translational Laboratory & Hypertension Unit, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.
出版信息
Eur Heart J. 2020 Jun 7;41(22):2067-2069. doi: 10.1093/eurheartj/ehaa487.
Abstract
摘要
相似文献
1
Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.新型冠状病毒肺炎大流行中的肾素-血管紧张素系统抑制剂：抗高血压药物的影响
Eur Heart J. 2020 Jun 7;41(22):2067-2069. doi: 10.1093/eurheartj/ehaa487.
2
5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19.五类降压药与新冠病毒检测阳性或重症新冠无关。
Ann Intern Med. 2020 Sep 15;173(6):JC35. doi: 10.7326/ACPJ202009150-035.
3
Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.关于在新冠疫情背景下成人和儿童使用肾素-血管紧张素系统降压阻滞剂的考量
Bol Med Hosp Infant Mex. 2020;77(5):274-281. doi: 10.24875/BMHIM.20000158.
4
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
5
[Hypertension, RAAS blockade and risk in COVID-19 patients].[高血压、肾素-血管紧张素-醛固酮系统阻断与新冠病毒感染患者的风险]
Lakartidningen. 2020 Jun 23;117:20102.
6
COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?2019冠状病毒病与肾素-血管紧张素-醛固酮系统阻滞剂：阿利吉仑会是一个合适的选择吗？
Turk Kardiyol Dern Ars. 2020 Oct;48(7):631-634. doi: 10.5543/tkda.2020.64072.
7
Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.肾素-血管紧张素系统抑制剂在 COVID-19 大流行期间高血压管理中的应用。
J Physiol Pharmacol. 2020 Apr;71(2). doi: 10.26402/jpp.2020.2.01. Epub 2020 Jul 2.
8
Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎患者的预后：一项病例系列研究。
Hypertension. 2020 Aug;76(2):e10-e12. doi: 10.1161/HYPERTENSIONAHA.120.15312. Epub 2020 May 8.
9
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.2019冠状病毒病大流行期间肾素-血管紧张素系统阻滞剂的使用：早期指南及不断演变的证据
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
10
What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?在新冠病毒肺炎（COVID-19）中，关于肾素-血管紧张素系统抑制剂的应用，需要何种证据来指导实践？
Hypertension. 2020 Sep;76(3):665-669. doi: 10.1161/HYPERTENSIONAHA.120.15712. Epub 2020 Aug 12.
引用本文的文献
1
Renin-Angiotensin System Inhibitors and the COVID-19 Pandemic.肾素-血管紧张素系统抑制剂与新冠疫情
Am J Hypertens. 2023 Jun 15;36(7):360-362. doi: 10.1093/ajh/hpad031.
2
Sustainable spectrophotometric determination of antihypertensive medicines reducing COVID-19 risk via paired wavelength data processing technique - Assessment of purity, greenness and whiteness.通过配对波长数据处理技术对降低COVID-19风险的抗高血压药物进行可持续分光光度法测定——纯度、绿色度和白度评估
Sustain Chem Pharm. 2022 Oct;29:100806. doi: 10.1016/j.scp.2022.100806. Epub 2022 Aug 15.
3
Eco-friendly spectrophotometric evaluation of triple-combination therapies in the treatment strategy of patients suffering from hypertension during coronavirus pandemic - Spectralprint recognition study.生态友好型分光光度评价法在冠状病毒大流行期间高血压患者三联治疗策略中的应用——光谱识别研究。
Spectrochim Acta A Mol Biomol Spectrosc. 2022 Nov 5;280:121523. doi: 10.1016/j.saa.2022.121523. Epub 2022 Jun 18.
4
The Johns Hopkins Ciccarone Center's expanded 'ABC's approach to highlight 2020 updates in cardiovascular disease prevention.约翰·霍普金斯西卡罗内中心扩展了“ABC方法”，以突出2020年心血管疾病预防方面的更新内容。
Am J Prev Cardiol. 2021 Apr 5;6:100181. doi: 10.1016/j.ajpc.2021.100181. eCollection 2021 Jun.
5
COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.新型冠状病毒肺炎：感染期间多个系统失衡和心脏及抗凝治疗选择及剂量的重要性。
Mol Biol Rep. 2021 Mar;48(3):2917-2928. doi: 10.1007/s11033-021-06333-w. Epub 2021 Apr 10.
6
[Cardiovascular preventive recommendations. PAPPS 2020 update].[心血管预防建议。PAPPS 2020更新版]
Aten Primaria. 2020 Nov;52 Suppl 2(Suppl 2):5-31. doi: 10.1016/j.aprim.2020.08.002.
7
The saga continues: is COVID-19 a cardiopulmonary disease?故事仍在继续：新冠病毒肺炎是一种心肺疾病吗？
Eur Heart J. 2020 Jun 7;41(22):2041-2044. doi: 10.1093/eurheartj/ehaa502.
8
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.COVID-19 及相关肺炎患者的预后因素和结局预测指标：一项回顾性队列研究。
Biosci Rep. 2020 Dec 23;40(12). doi: 10.1042/BSR20203455.
9
Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.血管紧张素转换酶 2 及其与 SARS-CoV-2 疾病关联的 20 年研究进展。
Clin Sci (Lond). 2020 Oct 16;134(19):2645-2664. doi: 10.1042/CS20200901.
本文引用的文献
1
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.高血压和降压治疗与 COVID-19 死亡率的关联：一项回顾性观察研究。
Eur Heart J. 2020 Jun 7;41(22):2058-2066. doi: 10.1093/eurheartj/ehaa433.
2
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
3
Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis.新型冠状病毒肺炎中过度炎症反应和肾素-血管紧张素-醛固酮系统紊乱：疑似高凝状态和微血管免疫血栓形成的新假说。
Clin Chim Acta. 2020 Aug;507:167-173. doi: 10.1016/j.cca.2020.04.027. Epub 2020 Apr 26.
4
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.新型冠状病毒肺炎与血栓栓塞性疾病：预防、抗栓治疗与随访的相关问题：美国心脏病学会临床实践更新。
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
5
Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与血管紧张素转换酶2的结合：临床意义
Cardiovasc Res. 2020 Jun 1;116(7):e87-e89. doi: 10.1093/cvr/cvaa096.
6
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.中性肽链内切酶抑制剂-血管紧张素II受体阻滞剂组合（沙库巴曲/缬沙坦）：应用于2019冠状病毒病患者的理论依据
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):135-136. doi: 10.1093/ehjcvp/pvaa028.
7
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
8
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
9
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
10
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
Zotero 插件